Press Releases

YEAR
Toggle Summary Nabriva Therapeutics Appoints Francesco Maria Lavino as Chief Commercial Officer
Further Strengthens Management Team of Industry Veterans to Support Commercialization of Potential New Antibiotic for Community-Acquired Bacterial Pneumonia DUBLIN, Ireland and KING OF PRUSSIA, Pa. , July 11, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical
View HTML
Toggle Summary Nabriva Therapeutics Appoints Carrie Bourdow and Colin Broom to the Board
DUBLIN, Ireland, June 26, 2017  – Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced the
View HTML
Toggle Summary Nabriva Therapeutics plc Successfully Concludes Tender Offer for Outstanding Common Shares of Nabriva Therapeutics plc and Outstanding American Depositary Shares of Nabriva Therapeutics plc
DUBLIN, Ireland , June 26, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (" Nabriva Therapeutics ") today announced that it has successfully concluded its previously announced tender offer related to the exchange of common shares (" Nabriva AG Common Shares ") of Nabriva Therapeutics plc ("
View HTML
Toggle Summary Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, 2017
VIENNA, Austria and KING OF PRUSSIA, Pa. , June 05, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class
View HTML
Toggle Summary Nabriva Therapeutics to present data at ASM Microbe supporting ongoing Phase 3 clinical development program for lefamulin
Four abstracts demonstrate potential for lefamulin as a first-line, empiric treatment for patients with community-acquired bacterial pneumonia VIENNA, Austria and KING OF PRUSSIA, Pa. , June 02, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical
View HTML
Toggle Summary Nabriva Commences Previously Announced Tender Offer Related to the Proposed Redomicile of its Holding Company from Austria to Ireland
DUBLIN, Ireland , May 23, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (" Nabriva Ireland ") today commenced the previously announced tender offer related to the exchange of American depositary shares (" Nabriva AG ADSs ") and common shares (" Nabriva AG Common Shares ") of Nabriva
View HTML
Toggle Summary Corrected - Nabriva Therapeutics Reports First Quarter 2017 Financial Results
- Expects top-line data from LEAP 1 CABP Phase 3 trial in third quarter 2017 and from LEAP 2 CABP Phase 3 trial in first quarter 2018 Vienna, Austria / King of Prussia, PA, May 12, 2017 – Nabriva Therapeutics AG (NASDAQ: NBRV), a clinical stage biopharmaceutical company engaged in the research and
View HTML
Toggle Summary Nabriva Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference
VIENNA, Austria and KING OF PRUSSIA, Pa. , April 19, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin
View HTML
Toggle Summary Nabriva Announces the Proposed Redomicile of its Holding Company from Austria to Ireland, by means of an Exchange Offer
VIENNA, Austria , April 17, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV) (" Nabriva AG ") announced that its supervisory board and management board approved the relocation of the holding company of Nabriva AG and its subsidiaries (" Nabriva Group ") from Austria to Ireland (the "
View HTML
Toggle Summary Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin
Nine abstracts support potential for lefamulin as a first-line, empiric treatment for patients with community-acquired bacterial pneumonia VIENNA, Austria and KING OF PRUSSIA, Pa. , April 13, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company
View HTML

For Media Inquiries

PR@nabriva.com


For Investor Relations

David Garrett
Vice President, Corporate Controller and Head of Investor Relations
Nabriva Therapeutics plc

E-mail: david.garrett@nabriva.com